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summARy – Parathyroid gland carcinoma is a rare malignancy. The tumor is mostly functi-
oning, causing severe hyperparathyroidism, with high serum calcium level and severe bone disease. 
Non-functioning parathyroid carcinomas are extremely rare. We report on a 60-year-old male pati-
ent admitted to eNt department due to a large neck tumor mass compressing the thyroid and tra-
chea. Preoperatively, thyroid hormone, parathyroid hormone (Pth) and calcium serum levels were 
normal. The following immunohistochemical markers (dAKo, denmark) were used: bcl-2; Cd-
10; Chromogranin-A; Cyclin-d1; emA; Ki-67; mdm-2; p-53; PgP-9,5; RCC; synaptophysin; 
Thyroglobulin; and ttf-1. immunohistochemical analysis indicated the diagnosis of a primary 
parathyroid gland carcinoma. tumor cells showed diffusely positive immunohistochemical staining 
with chromogranin-A and PgP-9,5, positive staining of variable intensity with synaptophysin, and 
weakly positive reaction with emA. Also, the cytoplasm of tumor cells was diffusely positively 
stained with bcl-2, while the nuclei showed positive reaction with p-53 oncogene and ttf-1. The 
remaining markers (Cd-10, cyclin-d1, Ki-67, mdm-2, RCC and thyroglobulin) were negative. 
four years after the surgery, the patient died from renal carcinoma pulmonary metastases and liver 
cirrhosis complications. in conclusion, non-functioning parathyroid gland carcinoma is a very rare 
disease. detailed immunohistochemical analysis is needed to distinguish it from other thyroid and 
parathyroid neoplasms and metastatic carcinoma. surgical treatment is presently the best mode of 
therapy.
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Introduction 
Parathyroid carcinoma is a rare malignancy of the 
parathyroid gland1. it usually occurs in patients older 
than 30, equally in male and female. There is no known 
geographical variation in its prevalence. in most cases, 
the etiology of disease is unknown. it may be associat-
ed with genetic disease, hyperparathyroidism, jaw tu-
mor syndrome, and with a history of neck irradiation2. 
Parathyroid carcinoma is a slow-growing tumor, has 
a tendency of local recurrence, and metastasizes late. 
These tumors are mostly functioning, causing severe 
hyperparathyroidism with high serum calcium level, 
severe bone diasease and renal stones2-5. The onset and 
symptoms of hyperparathyroidism are usually more 
severe than those that are associated with a benign 
disease. Palpable mass in the neck is seen in approxi-
mately 50% of patients. At present, surgical resection 
is the only effective treatment option. The reported 
overall 5-year survival rate ranges from 50% to 75%. 
A significant number of patients die from recurrent 
disease 5 years or longer after the initial treatment. 
only 30% of patients have a long-term cure rate1-5. 
We report on a 60-year-old male patient admitted to 
the ear Nose and Throat department due to a large 
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neck tumor mass, which was compressing the thyroid 
and trachea. After thorough clinical observation, the 
neck tumor was surgically removed. Pathologic find-
ing pointed to the diagnosis of primary parathyroid 
gland carcinoma. 
Case Report
A 60-year-old male patient was admitted to the 
eNt department for a clinically palpable large tumor 
on the left side of the neck. Routine laboratory find-
ings: thyroid hormone, thyroid-stimulating hormone, 
parathyroid hormone, calcium, phosphates, alkaline 
phosphatase, and urine were within the reference 
values (data not shown). No previous thyroid abnor-
malities or other concomitant diseases were present. 
however, the patient had previously been treated at 
urology department for renal cell carcinoma, which 
had been surgically removed. it was well differenti-
ated, composed of alveolar nests of clear cells (fig. 
1). The tumor was limited to the upper pole of the 
kidney, with a 5-cm diameter. There were no meta-
static deposits in the aortal and interaortocaval lymph 
nodes. Radiological findings (computed tomography) 
revealed dislocation of the larynx and trachea by an 
expanding tumor mass attached to the left lobe of the 
thyroid gland. The tumor spread superiorly from the 
upper corn of the thyroid cartilage and inferiorly to 
the upper mediastinum and the aortic arch, measur-
ing 6×6×10 cm in diameter. The trachea was severely 
compressed to the right, while the lumen was limited 
to the size of 12 mm (fig. 2). The tumor was sur-
gically removed together with resection of the left 
thyroid lobe, with preservation of the recurrent laryn-
geal nerve and the contralateral thyroid lobe. lymph-
adenectomy of the central compartment of the neck 
was also performed. on pathologic analysis, macro-
scopic appearance showed the extremely large, brown-
reddish to grey in color, partially necrotic tumor with 
broad areas of hemorrhage and fibrosis. microscopi-
cally, tumor tissue showed a trabecular and alveolar 
pattern of predominantly watermelon cells with nu-
clei like seeds and numerous mitotic figures, separated 
by thick fibrous bands. A minor number of cells had 
bright basophilic cytoplasm and smaller round nuclei 
Fig. 1. Simultaneous renal clear cell carcinoma. Alveolar 
pattern (HE; ×100).
Fig. 2. Computed tomography scan revealed massive tumor 
on the left side of the neck, which compressed the larynx and 
trachea on the right. 
Fig. 3. Non-functioning carcinoma of the parathyroid gland: 
positive immunohistochemical reaction in nuclei (TTF-1; 
×400) 
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with finely dispersed chromatin and nucleoli. The tu-
mor was significantly vascularized with broad areas of 
hemorrhage and hemosiderin deposits. tumor capsule 
was infiltrated with clusters of atypical cells, adher-
ent to normal thyroid gland. There were no metastatic 
deposits present in the lymph nodes. on immunohis-
tochemical analysis, tumor cells showed diffusely pos-
itive reaction with chromogranin-A, p-53 oncogene, 
and thyroid transcription factor-1 (ttf-1) (fig. 3). 
Cyclin-d1, antigen Ki-67, murine double minute 2 
protein (mdm2), and thyroglobulin protein were all 
negative. There was strongly positive expression of 
protein gene product 9,5 (PgP-9,5) (fig. 4). due to 
the lack of immunostaining markers, parathormone 
staining was not performed. to exclude the metas-
tases of the simultaneous renal cell carcinoma, the 
immunostaining for renal cell carcinoma (RCC) was 
also performed and showed no positivity. The postop-
erative period was uneventful. Parathyroid hormone 
and calcium serum levels were within the reference 
values. four years following the surgery, the patient 
died due to the renal cell carcinoma pulmonary me-
tastases (metastatic nests showed intensively positive 
immunohistochemical expression of markers charac-
teristic of RCC) and hepatic cirrhosis complications. 
Discussion 
Parathyroid carcinomas account for less than 1% 
of primary hyperparathyroidism cases. The majority 
(95%) of parathyroid carcinomas are functioning and 
secrete parathyroid hormone. Non-functioning para-
thyroid gland carcinoma is extremely rare. multiple 
endocrine neoplasia syndrome type 1 (meN 1), al-
though rarely affected by carcinomas, has been associ-
ated with parathyroid carcinoma. in the present case, 
the tumor presented as a palpable neck mass severely 
compressing adjacent anatomic structures, i.e. trachea 
and larynx. The patient’s pre- and postoperative serum 
calcium and parathyroid hormone levels were normal, 
suggesting a non-functioning form of the parathyroid 
gland tumor. macroscopically, parathyroid carcinoma 
can be described as a grayish, hard lobulated tumor 
surrounded by a dense fibrotic capsule. its adherence 
and invasion of the surrounding structures is an im-
portant sign of malignancy. The possible criteria have 
been suggested for diagnosing malignancy, which 
were also seen in the present case: thick fibrous bands, 
areas of necrosis and hemorrhage, hemosiderin de-
posits, pleomorphic nuclei with numerous pathologic 
mitoses, invasion of the capsule and adhesion for the 
left thyroid globe. others consider that cellular atyp-
ia, nuclear pleomorphism and macronucleoli are signs 
of malignancy5. Cryns et al.6 were the first to report 
that immunohistochemical reaction with monoclonal 
antibody against retinoblastoma (Rb) protein is com-
monly absent in parathyroid carcinomas and almost 
always present in adenomas. Rb protein is a cell-cycle 
regulator that blocks transformation from the g1 
(resting) in the s (synthesis) cellular cycle phase, and 
directly reacts with cyclin-d1. Cyclin-d1 was found 
to be positive in a small percentage of normal parathy-
roid tissues (<6%) and may be used as the additional 
technique in distinguishing between benign and 
malignant parathyroid tumors7. in the present case, 
cyclin-d1 was found to be negative. on the contrary, 
dotzenrath et al.8 and Kytola et al.9 report that Rb pro-
tein cannot be used in differentiation between benign 
and malignant parathyroid tumors. They obtained 
much stronger reaction in carcinomatous cells stained 
with Ki-67 proliferation marker. furthermore, Ab-
bona et al. found statistically significant differences 
between adenomas and carcinomas using Ki-67 pro-
liferation marker10. today, it is considered that only 
Ki-67 and p-27 proteins are efficient markers to dis-
tinguish adenoma and carcinoma, whereas others such 
as p-53 and bcl-2 are not reliable11-13. stojadinovic et 
al. report that a multiple-marker phenotype including 
Fig. 4. Non-functioning carcinoma of the parathyroid gland: 
strongly positive immunohistochemical reaction (PGP-9,5; 
×200).
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p-27, bcl-2, Ki-67 and mdm-2 was useful in defining a 
subset of benign tumors but that carcinoma displayed 
a complex range of multi-marker phenotypes, some of 
which were not specific13. in the present case, the Ki-
67 protein, mdm-2, RCC (thus excluding metastases 
of simultaneous RCC) and thyroglobulin protein (thus 
excluding thyroid tumors) were all negative. due to 
the lack of the specific gold-standard histopathologic 
criteria in recognition of parathyroid carcinomas, up 
to 86% of cases are not initially recognized and re-
ceive inadequate surgical resection, or the diagnosis 
is made after disease relapse, thus limiting treatment 
options. furthermore, about 20% of patients with ap-
parently sporadic carcinoma may be manifesting a 
form of hyperparathyroidism-jaw tumor syndrome, 
i.e. a hereditary multitumor syndrome characterized 
by hRPt2 gene mutations. This gene has recently 
been identified as a tumor suppressor gene in para-
thyroid carcinoma, encoding a novel protein product 
named parafibromin. tan et al. suggest that the loss 
of parafibromin immunoreactivity could distinguish 
parathyroid carcinoma from benign pathologies of 
primary hyperparathyroidism14.
Another novel gene associated with the parathy-
roid tumor carcinogenesis is the uChl1 protein gene 
product 9,5 (PgP-9,5). it is expressed in neuronal and 
neuroendocrine tissues, as well as during embryonic 
development in the parathyroid glands of the rat. Posi-
tive diffuse staining for PgP-9,5 has a 78% sensitivity 
and 100% specificity for parathyroid malignancies. in 
the present case, the tumor showed high positive ex-
pression for PgP-9,5 that confirmed the diagnosis of 
parathyroid gland carcinoma15. With the use of these 
two highly sensitive and specific markers, hyperpara-
thyroidism tumors are classified in categories with 
high and low risk malignancy and atypical adenomas. 
high-risk carcinomas are positive for parafibromin 
and PgP-9,5, whereas low-risk ones are positive for 
PgP-9,5 but negative for parafibromin. Atypical tu-
mors which are parafibromin positive and PgP-9,5 
negative should be classified as atypical adenomas and 
treated with simple surgical excision.
Conclusion
Non-functioning parathyroid carcinoma is ex-
tremely rare. These tumors are associated with nor-
mocalcemia and normal serum parathyroid hormone 
level. They need to be distinguished from other func-
tioning parathyroid and metastatic carcinoma in order 
to be properly treated. immunohistologic pathologic 
analysis can be a valuable method in the diagnosis of 
parathyroid carcinoma. surgical removal remains the 
best possible treatment option. 
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sažetak
NefuNKCioNAlNi KARCiNom PARAtiRoidNe ŽliJeZde: PRiKAZ sluČAJA
A. Krvavica, M. Kovačić, I. Baraka i M. Rudić 
Karcinom paratiroidne žlijezde je rijedak maligni tumor. tumor je najčešće hormonski aktivan i uzrokuje teški oblik 
hiperparatiroidizma s visokom serumskom razinom kalcija, poremećajima koštane gustoće i bubrežnim kamencima. Ne-
funkcionalni paratiroidni karcinom je iznimno rijedak. Prikazuje se slučaj 60-godišnjeg bolesnika koji je primljen na 
odjel otorinolaringologije zbog velikog tumora vrata koji je komprimirao grkljan i dušnik. Prijeoperacijski su serumske 
vrijednosti hormona štitnjače, paratiroidnog hormona i kalcija bile unutar referentnih vrijednosti. Korišteni su slijedeći 
imunohistokemijski biljezi: (dAKo, danska): bcl-2; Cd-10; Chromogranin-A; Cyclin-d1; Ki-67; mdm-2; p-53; RCC; 
synaptophysin; Thyroglobulin i ttf-1. imunohistokemijskom analizom tumora postavljena je dijagnoza primarnog kar-
cinoma paratiroidne žlijezde. tumorske stanice su pokazale difuzno pozitivnu imunoreakciju s kromograninom i PgP-
9,5, pozitivnu reakciju različitog intenziteta sa sinaptofizinom, te slabo pozitivnu reakciju na emA. u citoplazmi je nađena 
umjereno pozitivna reakcija na bcl-2, a jezgre su bile pozitivne na p-53 i ttf-1, dok su ostali biljezi bili nereaktivni. Četiri 
godine nakon operacije bolesnik je umro od posljedica plućnih metastaza karcinoma bubrega i dekompenzirane jetrene 
ciroze. u zaključku, nefunkcionalni karcinom paratiroidne žlijezde je vrlo rijedak i težak za dijagnosticiranje. detaljnim 
imunohistokemijskim metodama potrebno ga je diferencirati od ostalih tumora štitne i paratiroidne žlijezde i metastat-
skog karcinoma. Kirurško liječenje danas predstavlja optimalan oblik terapije.
Ključne riječi: Paratiroidni tumori – dijagnostika; Paratiroidni tumori – patologija; Nefunkcionalni paratiroidni tumori

